Biblio

Author Title Type [ Year(Asc)]
Filters: Author is van de Loosdrecht, Arjan A  [Clear All Filters]
2024
van Spronsen MF, Van Gassen S, Duetz C, Westers TM, Saeys Y, van de Loosdrecht AA. Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells. Leukemia. 2024.
2023
Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MWai, van Roessel C, Janssen JJW, Biemond BJ, van de Loosdrecht AA, Hazenberg MD, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023.
van Spronsen MF, Hanekamp D, Westers TM, van Gils N, Vermue E, Rutten A, Jansen JH, Lissenberg-Witte BI, Smit L, Schuurhuis GJ, et al. Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. Leukemia. 2023.
Ngai LLam, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, van Marsbergen LOudshoorn-, Scholten WJ, Snel AN, et al. Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood. 2023.
2022
Bachas C, Duetz C, van Spronsen MF, Verhoeff J, Vallejo JJGarcia, Jansen JH, Cloos J, Westers TM, van de Loosdrecht AA. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry. Cytometry B Clin Cytom. 2022.
Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12(12):166.
2021
Subirá D, Alhan C, Oelschlaegel U, Porwit A, Psarra K, Westers TM, Golbano N, Nilsson L, van de Loosdrecht AA, de Miguel D. Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome. Ann Hematol. 2021.
2020
Hanekamp D, Ngai LLam, Janssen JJwm, van de Loosdrecht AA, Ossenkoppele GJ, Cloos J. Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells. Blood. 2020.
Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermak J, Dinmohamed AG, Eeltink C, Eggmann S, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
2018
Hout FEMIn 't, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, et al. TCF4 promotes erythroid development. Exp Hematol. 2018.
2014
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EWA, Vonk MC, Schattenberg AV, et al. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial. JAMA. 2014;311(24):2490-2498.
2013
Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Cañizo C, Porta MGDella, Fenaux P, Gattermann N, Germing U, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013.